Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

NICE provisionally rejects drug treatment for Crohn’s disease

  • Comment

In draft guidance, the National Institute for Health and Care Excellence has not recommended the drug vedolizumab (Entyvio) to treat people with Crohn’s disease.

NICE said the expert committee appraising the drug had decided that the evidence for its efficacy was “too uncertain” and that the drug “was not likely” to represent good value for the NHS.

Professor Carole Longson, director of the institute’s Health Technology Evaluation Centre, said: “Unfortunately the maker of vedolizumab did not give the committee enough information to show how well it worked when compared to other treatments.

“Unfortunately, because the committee could not be sure that vedolizumab worked at least as well as other currently available drugs they concluded that vedolizumab was unlikely to be a cost-effective use of NHS money,” added Professor Longson.

“We are disappointed not to be able to say ‘yes’ to this drug,” she said. “Fortunately effective drugs are already available within the NHS for Crohn’s disease.”

“We have to be sure that a drug is both effective and cost-effective before it can be recommended”

Carole Longson

Healthcare professionals and members of the public are able to comment on the preliminary recommendations, which are available for consultation until 27 January.  

Final guidance on the use of vedolizumab, which is manufactured by Millennium Pharmaceuticals, is expected to be published in May.

Until then, NICE told NHS bodies they should make decisions locally on the funding of specific treatments for Crohn’s disease, which affects about 115,000 people in the UK.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs